Acute On Chronic Liver Failure (ACLF) Clinical Trial Pipeline Analysis: 3+ Key Companies Shaping the Future of ACLF Therapeutics | DelveInsight

DelveInsight's Acute On Chronic Liver Failure (ACLF) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline ACLF therapies in various stages of clinical development. The report provides insights into 3+ companies and 3+ pipeline drugs in the Acute On Chronic Liver Failure pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Acute On Chronic Liver Failure Clinical Trial Landscape Report

• DelveInsight's ACLF pipeline report depicts a developing space with 3+ companies working to develop 3+ pipeline therapies for Acute On Chronic Liver Failure treatment.
• Key ACLF companies such as Yaqrit Discovery Ltd/Takeda Pharmaceutical Company Limited, Gyre Therapeutics, Inc., and GENFIT.
• Promising ACLF pipeline therapies in various stages of development include YAQ005/(TAK-242), F573, and G1090N.

Request a sample and discover the recent advances in Acute On Chronic Liver Failure treatment drugs https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Acute On Chronic Liver Failure (ACLF)?

Acute On Chronic Liver Failure (ACLF) is a clinical syndrome of sudden hepatic decompensation occurring in patients with pre-existing chronic liver disease and associated with one or more extrahepatic organ failures and increased mortality.
ACLF commonly occurs in patients with chronic liver disease, particularly cirrhosis, and is frequently observed among patients hospitalized with acute decompensation. The condition may present with jaundice, hepatic encephalopathy, coagulopathy, ascites, acute kidney injury, and systemic inflammation or infection. As the disease progresses, multiple organ dysfunction may develop, including respiratory failure, circulatory instability, and worsening neurological status.
The pathophysiology involves an acute precipitating event that causes hepatocyte injury and triggers a cascade of inflammatory cytokines and chemokines. This systemic inflammatory response, together with impaired liver regeneration and immune dysfunction, can increase susceptibility to infection, multi-organ failure, and death.
Diagnosis of ACLF is made in patients with acute decompensation of liver cirrhosis accompanied by organ failure, with the Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) score used to assess organ failure.
There is currently no specific therapy for ACLF. Treatment primarily focuses on identifying and treating precipitating events, providing supportive care, managing complications such as infection, renal dysfunction, and hepatic encephalopathy, and providing organ support when required. Liver transplantation remains an important treatment option for selected patients with severe ACLF.

Emerging Acute On Chronic Liver Failure Drug Profiles

G1090N: GENFIT
G1090N is a reformulated version of nitazoxanide (NTZ) being investigated for Acute On Chronic Liver Failure. The formulation is designed to improve effectiveness in patients with severe liver and renal impairment. G1090N has antiviral and anti-inflammatory properties and exerts its therapeutic effects primarily through modulation of systemic inflammation and immune responses.
Its active metabolite, tizoxanide, has been shown to inhibit pro-inflammatory signaling pathways in circulating immune cells, including suppression of lipopolysaccharide-induced cytokines such as IL-6 and TNF-α. The drug is currently in the Phase I stage of development for the treatment of Acute On Chronic Liver Failure.

YAQ005/(TAK-242): Yaqrit Discovery Ltd/Takeda Pharmaceutical Company Limited
YAQ005/(TAK-242) is an investigational therapy included in the Acute On Chronic Liver Failure pipeline landscape. It represents one of the key emerging products being evaluated for ACLF and is covered in DelveInsight's pipeline assessment.

F573: Gyre Therapeutics, Inc.
F573 is an investigational pipeline therapy being developed for Acute On Chronic Liver Failure. It is among the key products identified in DelveInsight's ACLF pipeline landscape and is included in the report's assessment of emerging therapeutic approaches for the condition.

Learn more about the novel and emerging Acute On Chronic Liver Failure pipeline therapies https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Acute On Chronic Liver Failure Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Acute On Chronic Liver Failure Companies: Yaqrit Discovery Ltd/Takeda Pharmaceutical Company Limited, Gyre Therapeutics, Inc., GENFIT
• Key Acute On Chronic Liver Failure Pipeline Therapies: YAQ005/(TAK-242), F573, G1090N.

Dive deep into rich insights for new drugs for Acute On Chronic Liver Failure treatment, visit https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Acute On Chronic Liver Failure Pipeline Report Introduction
2. Acute On Chronic Liver Failure Pipeline Report Executive Summary
3. Acute On Chronic Liver Failure: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute On Chronic Liver Failure Pipeline Therapeutics
6. Acute On Chronic Liver Failure Pipeline: Late Stage Products (Phase III)
7. Acute On Chronic Liver Failure Pipeline: Mid Stage Products (Phase II)
8. Acute On Chronic Liver Failure Pipeline: Early Stage Products (Phase I)
9. Acute On Chronic Liver Failure Pipeline: Preclinical and Discovery Stage Products
10. Acute On Chronic Liver Failure Pipeline Therapeutics Assessment
11. Inactive Products in the Acute On Chronic Liver Failure Pipeline
12. Key Companies
13. Key Products in the Acute On Chronic Liver Failure Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Acute On Chronic Liver Failure pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.